United States is studying to announce this week the recommendation that almost all its citizens should receive a booster dose of Covid-19 vaccine.
This third puncture should occur eight months after receiving the second dose, so inoculation should begin in mid-September, indicate the US newspapers ‘The New York Times’ and ‘The Washington Post’, which cite officials familiar with the decision.
Citizens will receive the same vaccine that they injected Initially and the same order as in the previous vaccination campaign will be followed: first the homes for the elderly, followed by the health, elderly and vulnerable people.
This Monday, the pharmaceutical alliance Pfizer / BioNTech asked the United States health authorities for the future authorization of a third dose for its vaccine against Covid-19, and presented them with preliminary encouraging results.
‘The data we’ve seen so far suggests that a third dose of our vaccine triggers antibody levels significantly exceeding those seen after the two initially scheduled doses”Explained Albert Bourla, CEO of Pfizer, quoted in a press release.
Therefore, the two companies have ‘submitted phase 1 data [de ensayos clínicos] to United States Drug and Drug Administration (FDA) to support the evaluation of a third dose, or booster dose, of the Covid-19 vaccine for future approval.
These results will also be presented to the European Medicines Agency (EMA) and to other regulatory authorities “in the coming weeks,” he said. “Phase 3 results are expected soon and will be presented to the FDA, EMA and other regulatory authorities around the world,” the statement said.
Pfizer had already communicated these results, which are related to the initial strain of the virus but also against the Beta and Delta variants, the latter being the origin of a strong resurgence of the epidemic around the world.
This booster dose, given between 6 and 12 months after the first two injections“It could help reduce infection and disease rates in previously vaccinated people, and better control the spread of virus variants,” said Ugur Sahin, head of BioNTech.